Nephrocare Health Services to hold 17th AGM on Aug 12, 2026, for financial year 2025-26 results and ESOP approval
Nephrocare Health Services will hold its 17th AGM on August 12, 2026, to adopt FY26 financial statements and approve the ESOP 2026 plan. The AGM will cover re-appointment of a director and a clarificatory amendment to the CMD's remuneration. Remote e-voting is open from August 8-11, 2026.
The AGM notice details important upcoming decisions regarding financial statements, director re-appointment, and employee stock options, which are material to the company's governance and future operations. Approval of the ESOP scheme could impact future share dilution and employee compensation.
The announcement is a routine notice for an AGM and does not contain any specific financial performance data or significant corporate actions that would warrant a positive or negative sentiment. It outlines upcoming discussions and approvals.
Nephrocare Health Services Limited has announced the notice for its 17th Annual General Meeting (AGM), scheduled to be held on Wednesday, August 12, 2026, at 2:30 PM IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM).
The AGM agenda includes the consideration and adoption of the audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026, along with the Auditors’ Report and Board’s Report. Additionally, the members will vote on the re-appointment of Mr. Gaurav Sharma as a Nominee Director.
Key special business items on the agenda include the approval for the introduction and implementation of the ‘NephroPlus Employee Stock Option Scheme, 2026’ (ESOP 2026), which allows for the grant of up to 20,06,814 employee stock options. Approval is also sought for extending the ESOP 2026 benefits to employees of subsidiary and associate companies.
Furthermore, the meeting will address a clarificatory amendment to the special resolution regarding the remuneration of Mr. Vikram Vuppala, Chairman & Managing Director, focusing on the definition of ‘Audited Adjusted Consolidated Operating EBITDA’ for performance-linked variable remuneration. An ordinary resolution will also be considered for the approval of the Promote Incentive Arrangement as per the Promote Agreement dated July 25, 2025.
The cut-off date for determining eligibility to attend the AGM and vote is Wednesday, August 5, 2026. The Register of Members and Share Transfer Books will remain closed from Thursday, August 6, 2026, to Wednesday, August 12, 2026. The remote e-voting facility will be open from Saturday, August 8, 2026, at 9:00 a.m. IST until Tuesday, August 11, 2026, at 5:00 p.m. IST.
What to do with a filing like this
Nephrocare Health Services Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Nephrocare Health Services Limited. Read the original for the full detail.